If the post suggests that the comparison between the arms failed, then it is a fabrication. Imo, there are not enough patients in the control arm because of crossover.
The control arm still has 99 patients in it. Cross over does not change that.
Many trials are confounded by crosspver. Virtually all the front line CI trials are having to deal with the use of CIs in the already approved 2nd/3rd line indications. That is the exact same as post-progression crossover.
Market Data 
Markets 
AI
